

Iron protein succinylate effective in iron deficiency

A controlled, double-blind multicentre trial involving over 1000 patients in Italy has shown that iron protein succinylate is as effective at treating iron deficiency as controlled-release iron sulfate.

Iron protein succinylate (ITF 282) was found to be clinically useful both in patients with insufficient dietary iron intake and in those with increased iron loss. It was also effective in elderly patients.

ITF 282 was very well tolerated, significantly more so than controlled-release iron sulfate. Therefore, the author concludes that due to its more favourable risk-to-benefit ratio ITF 282 should be used as a first-line treatment for iron deficiency.

Liguori L. Iron protein succinylate in the treatment of iron deficiency: controlled, double-blind, multicenter clinical trial on over 1,000 patients. *International Journal of Clinical Pharmacology Therapy and Toxicology* 31: 105-123, Mar 1993

800191686